Tumor immune microenvironment score predicts efficacy of immune checkpoint inhibitors-based regimens in advanced non-small cell lung cancer
Jiacheng Dai, Huan Yan, Yangqian Chen, Yuda Zhang, Zhe Huang, Zhaohui Ruan, Fang Tian, Haoyue Qin, Qinqin Xu, Jin Wang, Xing Li, Peng Cheng, Changbin Zhu, Nong Yang, Liang Zeng, Yongchang Zhang · 2025
Read Tumor immune microenvironment score predicts efficacy of immune checkpoint inhibitors-based regimens in advanced non-small cell lung cancer by Jiacheng Dai, Huan Yan, Yangqian Chen, Yuda Zhang, Zhe Huang, Zhaohui Ruan, Fang Tian, Haoyue Qin, Qinqin Xu, Jin Wang, Xing Li, Peng Cheng, Changbin Zhu, Nong Yang, Liang Zeng, Yongchang Zhang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12699922.txt.
Description
Jiacheng Dai and co-authors build a tumor environment score for lung cancer in a 2025 paper. Immune checkpoint drugs are now standard first care for advanced disease. Response rates vary widely, so patient selection needs help.
Ninety-six patients at Hunan Cancer Hospital were analyzed after care. All were new to treatment when they started immune-based regimens. Tumor samples taken before care underwent RNA sequencing. Genes tied to longer control of the disease fed the score. The score aims to predict who benefits before drugs begin. Readers see a step toward sparing unlikely responders harsh, costly therapy.
Catalog record
| CREATOR | Jiacheng Dai, Huan Yan, Yangqian Chen, Yuda Zhang, Zhe Huang, Zhaohui Ruan, Fang Tian, Haoyue Qin, Qinqin Xu, Jin Wang, Xing Li, Peng Cheng, Changbin Zhu, Nong Yang, Liang Zeng, Yongchang Zhang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |